Introduction
The homeobox (Hox) gene family encodes a group of transcription factors that are preferentially expressed during embryonic development and hematopoiesis and are commonly deregulated in acute lymphoblastic leukemia (ALL). 1 In hematopoiesis, the role of these transcription factors is the tight control and maintenance of stem cell differentiation and proliferation. 2 Hox gene family members contain conserved sequences of 183 nucleotides encoding a 61 amino acid, helix-turn-helix, DNAbinding motif. The core homeodomain DNA-binding motif recognizes the DNA sequence (T/G)NA(T/C). 3 In mammals, there are 39 different class I Hox genes organized into four clusters (A, B, C and D), located on four separate chromosomes. The clusters may be further grouped into subclasses based on their primary sequence into 13 paralog groups within each individual cluster. The mixed lineage leukemia (MLL) gene encodes a protein responsible for the maintenance of Hox gene expression, and translocations of the MLL gene are present at a high frequency in acute leukemia. 4 Deregulation of HoxA9 is associated with leukemia of both the myeloid and lymphoid lineages. [5] [6] [7] Gene-expression signatures of MLL-dependent T-and B-cell ALL showed upregulated expression of HoxA9. 1 In normal hematopoiesis, HoxA9 is strongly expressed in the CD34 þ population of hematopoietic precursors and subsequently downregulated as cells differentiate into the various subpopulations of blood cell types. 4 Overexpression of HoxA9 has been shown to perturb normal hematopoiesis in mice resulting in the development of leukemia. 8 Pim-1, 9,10 gp91Phox 11 and members of the Wnt gene family 12 have been reported to be targets of HoxA9 activity. However, a connection between HoxA9 and growth receptor signaling has not been previously described. In the present study, we have made use of a novel system to evaluate if HoxA9 expression will alter stromal cell-dependent growth. The cell line, B-lineage-2 (BLIN-2) , requires direct contact with viable bone marrow stromal cells for optimal survival and proliferation 13 and lacks expression of endogenous HoxA9. Parental BLIN-2 cells were stably transduced with an inducible HoxA9 retrovirus. Induction of HoxA9 activity increased the survival and proliferative capacity of BLIN-2 cells in the absence of stromal cell support, and resulted in surface expression of insulin-like growth factor-1 receptor (IGF-1R). HoxA9-mediated proliferative effects in BLIN-2 could be abrogated with specific inhibitors of IGF-1R. Furthermore, siRNA 'knockdown' of endogenous HoxA9 expression in cells bearing the MLL/AF4 chromosomal translocation resulted in loss of IGF-1R expression. These results are the first to functionally demonstrate a link between HoxA9 overexpression, induction of IGF-1R expression and proliferation of leukemic cells.
Materials and methods

Cell culture and cell lines
BLIN-2 and BLIN-3 cells have been described previously. [13] [14] [15] BLIN-2/MigR1 or BLIN-2/HoxA9:ER cells were generated by retroviral transduction, followed by fluorescence-activated cell sorting (FACS) for stable retroviral clones. BLIN-2 and BLIN-3 cells were maintained on stromal cell layers as previously described. [13] [14] [15] BLIN-3 cultures were supplemented with 10 ng ml À1 IL-7 (Peprotech, Rock Hill, NJ, USA). BLIN-2 cells were maintained in serum-free XVIVO-10 (Lonza BioScience, Walkersville, MD, USA) without phenol red. RS4;11 16 and SEMK2 17 cells were cultured in RPMI 1640 (Invitrogen, Carlsbad, CA, USA) supplemented with 10% heat-inactivated fetal calf serum.
Vectors
The full-length murine HoxA9 cDNA 8 (kind gift of G Sauvageau, Institute for Research in Immunology and Cancer, Montreal, Canada) was fused in frame with the hormone-binding domain of the human estrogen receptor, and tagged with the 14 aminoacid V5 epitope. The HoxA9:ER:V5 sequence was then cloned into the EcoRI and XhoI sites of the MigR1/internal ribosomal entry site (IRES)/green fluorescent protein (GFP) retroviral vector 18 to generate the HoxA9:ER construct.
Retroviral infection
Vectors were packaged with an amphotropic coat as described. 18 For retroviral transduction, BLIN-2 cells were plated at a density of 1 Â 10 6 cells per well in 6-well plates without stromal cell feeder layers in 1 ml of XVIVO-10 media, 4 ml of polybrene and 1 ml of filtered viral supernatant per well. Following 6 h incubation at 37 1C, 3 ml of XVIVO-10 media was added to each well. Following 24 h incubation at 37 1C, cells were transferred to flasks with stromal cell feeder layers and cultured for 48 h. Successfully transfected cells were FACS purified based on GFP expression. HoxA9 expression was confirmed by western blot analysis. Transfected cells were maintained in phenol red-free XVIVO-10 media in the presence of stromal cell layers.
Flow cytometry/cell sorting
Flow cytometry was performed using a FACSCalibur flow cytometer and analyzed using CellQuest-Pro software as described previously. 15 
Western blot
Western blots were performed as previously described. 15 Membranes were incubated with anti-HoxA9 (Upstate Biotechnology, Charlottesville, VA, USA); anti-c-Myb (Cell Signaling Technology, Beverly, MA, USA); anti-Pax5 (BD Transduction Laboratories, San Diego, CA, USA); anti-actin (Sigma, St Louis, MO, USA); anti-IGF-1Rb (Santa Cruz Biotechnology, Santa Cruz, CA); anti-HnRNP70 (kind gift from Dr Phillip Pekala, East Carolina University, USA) or anti-b-tubulin primary antibodies, suspended in 5% nonfat milk/Tris-buffered saline Tween-20 (TBST) (50 mM Tris, 150 mM NaCl, 0.19% Tween-20) or 1% bovine serum albumin/TBST and appropriate secondary antibodies (conjugated to horseradish peroxidase). For some experiments, cytoplasmic and nuclear fractions were separated using the NE-PER Kit (Pierce, Rockford, IL) as per manufacturer's instruction.
Cell growth and proliferation
Cell growth was evaluated via the 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay using CellTiter 96 reagent (Promega, Madison, WI, USA). Briefly, 2 Â 10 4 cells were washed 3 times in phenol red-free XVIVO-10 medium and were seeded in triplicate into 96-well plates in phenol red-free XVIVO-10 in the presence or absence of stromal cells. In some experiments, cells were treated with 4-hydroxytamoxifen (4HT; 1 mM) (Sigma), human recombinant insulin-like growth factor 1 (IGF-1; 50 ng ml À1 ) (Peprotech, Rocky Hill, NJ, USA), AG1024 (1 mg ml À1 ) (Calbiochem, La Jolla, CA, USA) and/or the A12 monoclonal antibody (mAb; 15 mg ml À1 ), at the indicated times, 20 ml of CellTiter 96 labeling (MTT) reagent was added to each well and incubated at 37 1C for 3 h. The absorbance was measured at 492 nm and is expressed as relative proliferation.
Unless indicated otherwise, all experiments were performed in triplicate.
Reverse transcriptase-PCR
Isolation of total RNA, cDNA synthesis and PCR were done as previously described. 15 
Southern blot analysis
Southern blotting was performed as described, 14 and membranes were probed with oligos internal to the PCR primers. Probes were HoxA9, 5
Transfection with siRNA
HoxA9 siRNA targeted to the sequence 5 0 -AATCAACAAAGA CCGAGCAAA-3 0 was synthesized by Ambion (Austin, TX, USA). Cells were transfected using an AMAXA Nucleofector per manufacturer's instructions and analyzed 24 h later by reverse transcriptase (RT)-PCR for HoxA9 and IGF-1R expression.
Immunoprecipitation
Cells were washed in phenol red-free XVIVO-10 medium and then cultured in the presence or absence of A12 mAb (15 mg ml À1 ) and 4HT (1 mM). Cells were treated with recombinant human IGF-1 (100 ng ml À1 ) for 5 min followed by the addition of 1 mM ethylene glycol tetraacetic acid (EGTA), 10 mM NaF, 1 mM sodium pyrophosphate and 0.1 mM b-glycerophosphate. Cells were washed in ice-cold PBS and lysed in buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 mM Na 3 VO 4 , 1 mM EGTA, 10 mM NaF, 1 mM sodium pyrophosphate and 0.1 mM b-glycerophosphate. Cellular protein (250 mg) in 300 ml of lysis buffer was precleared for 2 h at 4 1C with 20 ml of protein A/G plus-agarose beads (Santa Cruz Biotechnology). Immunoprecipitation was performed overnight at 4 1C with 2 mg of anti-IGF-1Ra antibody (clone 24-31) (Thermo Fischer Scientific, Fremont, CA, USA). Beads (20 ml) were added to samples and were incubated at 4 1C for 2 h. Beads were collected by centrifugation, washed twice in ice-cold lysis buffer and western blotting was performed, as described, using an anti-phosphotyrosine antibody (clone 4G10) (Upstate Biotechnology) per manufacturer's instructions to detect phosphorylation of the co-immunoprecipitated IGF-1Rb chain. IGF-1Rb chain identity was confirmed by probing the blot with anti-IGF-1Rb (Santa Cruz Biotechnology).
Enzyme-linked immunosorbent assays
Phosphorylated IGF-1R was detected using the STAR phospo-IGF-1R (TYR1135/1136) ELISA kit from Millipore (Billerica, MA, USA). The kit was used as per manufacturer's protocol, with 40 mg of whole-cell lysates per well. Plates were read of 450 nm using a Thermo Electron Corporation Multiskan EX plate reader.
Results
Expression of the HoxA9:ER fusion protein
To determine how HoxA9 expression may contribute to the growth and survival of B-lineage acute leukemia, the stromal cell-dependent pre-B ALL cell line, BLIN-2, was stably transduced with a 4HT-inducible HoxA9 retrovirus. This construct fuses the murine HoxA9 in frame with the hormonebinding region of the human estrogen receptor and a 14 amino acid encoding V5 epitope tag (HoxA9:ER). GFP is expressed as a separately translated protein, due to an IRES, in order to facilitate the identification of transduced cells ( Figure 1a) . Following retroviral transduction, BLIN-2/MigR1 and BLIN-2/ HoxA9:ER cells were FACS purified to greater than 92% ( Figure 1b ).
The HoxA9:ER fusion gene encodes a chimeric hormoneinducible protein, which allows for regulation of activity through the addition of the estrogen analog 4HT to the growth media. In the absence of the hormone inducer, the fusion protein is largely retained in the cytoplasm and is rapidly targeted for degradation via the proteasome pathway. 19 This strategy has been successfully used by others to study the activity of transcription factors and signaling molecules. 20, 21 The HoxA9:ER fusion protein is stabilized in the presence of 4HT which permits HoxA9 to localize in the nucleus. To test regulation of HoxA9:ER activity in BLIN-2 cells, BLIN-2/MigR1 and BLIN-2/HoxA9:ER cells were grown in the presence or absence of 4HT and analyzed for HoxA9:ER protein expression in nuclear and cytoplasmic protein fractions. Little HoxA9:ER was observed in BLIN-2/HoxA9:ER cells cultured in the absence of 4HT. However, when cultured in the presence of 4HT, HoxA9:ER was readily detected in the nuclear protein fraction (Figure 1c ). Pax5, a B-cell-specific transcription factor, was included as a control for a nuclear-specific protein. 22 Actin was found almost entirely in the cytoplasm. 23 This experiment confirms the stabilization and nuclear localization of the HoxA9:ER fusion protein in BLIN-2/HoxA9:ER cells treated with the estrogen analog 4HT. Electrophoretic mobility shift assay analysis confirmed that HoxA9:ER was capable of binding to the HoxA9 consensus DNA-binding site (data not shown).
BLIN-2/HoxA9:ER cells exhibit increased proliferation in the absence of stromal cell support
To examine the effects of HoxA9:ER on proliferation and survival, BLIN-2/MigR1 and BLIN-2/HoxA9:ER cells were cultured in the absence of stromal cell support with or without 1 mM 4HT for 5 days. Proliferation was determined by the MTT assay which measures mitochondrial respiration as a surrogate for cell number ( 
HoxA9 activation induces surface expression of IGF-1R
c-Myb has been reported to regulate IGF-1R expression. [25] [26] [27] IGF-1R has been reported to relieve leukemic cells of cytokine dependency. and have retained an absolute requirement for growth factor/ stromal cell contact for optimal growth and proliferation. 15 IGF-1R protein expression was observed in the cytokine and stromal cell-independent cell lines SEMK2 and RS4;11 ( Figure 4d) . Interestingly, IGF-1R expression was not observed in the IL-7 dependent, stromal cell-dependent cell line BLIN-3, that also lacks HoxA9 expression. Collectively, these results suggest that HoxA9 induces expression of IGF-1R, which in turn promotes growth factor/stromal cell-independent growth in leukemic cells.
Inhibition of IGF-1R blocks proliferation of BLIN-2/ HoxA9:ER
To determine if IGF-1R signaling was promoting enhanced survival and proliferation, BLIN-2/HoxA9:ER and BLIN-2/MigR1 cells were cultured on stromal cells with 4HT in the presence or absence of the IGF-1R tyrosine kinase inhibitor AG1024 (1 mg ml À1 ). BLIN-2/HoxA9:ER cells cultured in the presence of 4HT showed about an eightfold increase in proliferation after 10 days of culture (Figure 5a ). BLIN-2/HoxA9:ER proliferation was substantially decreased in the presence of AG1024. At day 5, there was nearly a 1.5-fold decrease in the proliferation of BLIN-2/HoxA9:ER cells treated with AG1024, and by day 10 these cells showed a twofold reduction in proliferation, as compared to cells treated with 4HT alone. BLIN-2/MigR1 cells cultured with 4HT exhibited nearly twofold less proliferation than that of the BLIN-2/HoxA:ER cells (Figure 5b ). BLIN-2/MigR1 cells exhibited little decreased proliferation when treated with AG1024.
Monoclonal antibody inhibition of the IGF-1R receptor
In a series of separate and independent experiments, BLIN-2/ HoxA9:ER cells were cultured on stromal cells and treated with the anti-IGF-1R mAb, A12, in the presence of 4HT. A12 is an IGF-1R-specific mAb that possesses high affinity for the IGF-1R receptor. 31 Binding of A12 to the IGF-1R receptor results in the rapid internalization and degradation of the receptor, thus inhibiting IGF-1R signaling and reducing cell surface receptor levels.
31 A12 has been reported to inhibit the growth of various cancer cell lines, including multiple myelomas, and has shown strong antitumor activity in nude mouse models. 31, 32 4HT-treated BLIN-2 and BLIN-2/HoxA9:ER cells were cultured in the presence of 15 mg of A12 mAb (Figures 5c and d) . A12 significantly inhibited the proliferation of BLIN-2/HoxA9:ER cells cultured with 4HT (Figure 5c ). A12 treatment had no effect on the proliferation of parental BLIN-2 cells (Figure 5d ). These results suggest that HoxA9-mediated expression of IGF-1R is 
Blocking IGF-1R signaling in RS4;11 cells inhibits proliferation
To test if blocking IGF-1R signaling would be effective at inhibiting the proliferation of an MLL-positive leukemia expressing endogenous HoxA9, RS4;11 cells were cultured in the presence or absence of A12 mAb. A12 treatment resulted in significant growth inhibition of RS4;11 cells (Figure 5e ). A12 growth inhibitory effects were observed as early as day 2. To determine if the observed RS4;11 growth effects were specific for IGF-1R inhibition, RS4;11 cells were cultured in the presence of IGF-1 or IGF-1 plus A12. Treatment with IGF-1 abrogated the effects of the A12 antibody resulting in increased proliferation of the A12-treated cells (Figure 5f ). These results indicate that inhibition of IGF-1R has an antiproliferative effect on cells overexpressing HoxA9. 
Loss of endogenous HoxA9 expression reduces IGF-1R expression in MLL/AF4-positive leukemia
Expression of IGF-1
Reverse transcriptase-PCR was used to determine if the various BLIN-2 transfectants and the stromal cell monolayers express IGF-1. As seen in Figure 7 , the stromal cells express the IGF-1 gene. In addition, IGF-1 expression was observed in BLIN-2, BLIN-2/MigR1 and BLIN-2/HoxA9:ER. No alteration in IGF-1 expression was observed upon induction of HoxA9 activity with the addition of 4HT (lane 6). IGF-1 expression was also observed in RS4;11 cells. These results suggest that HoxA9 may not regulate the expression of IGF-1, but this growth factor is expressed by both the leukemic cells and the supporting stromal cells.
Phosphorylation of IGF-1R
To demonstrate if IGF-1R was phosphorylated in BLIN-2/ HoxA9:ER cells, we performed immunoprecipitation of IGF-1R from IGF-1-stimulated cells (Figure 8 ). IGF-1Rb was co-immunoprecipitated with the IGF-1Ra chain. Phosphorylated IGF-1Rb was detected with the anti-phosphotyrosine antibody 4G10. Western blot analysis for phosphotyrosine residues revealed that phosphorylated IGF-1R could only be detected in BLIN-2/HoxA9:ER cells in the presence of 4HT and IGF-1 (Figure 8a) . Furthermore, treatment of cells with the A12 mAb inhibited phosphorylation of the receptor in BLIN-2/HoxA9:ER cells. To verify these results, we performed an enzyme-linked immunosorbent (ELISA) assay to detect IGF-1Rb phosphorylation (Figure 8b ). There was a 4.5-fold increase in IGF-1R phosphorylation in BLIN-2/HoxA9:ER in the presence of both 4HT and IGF-1 as compared to parental controls. IGF-1R phosphorylation in BLIN-2/HoxA9:ER cells was inhibited by treatment with the A12 mAb. 
Discussion
Overexpression of Hox genes has been widely associated with a variety of leukemias, including those bearing aberrations of the MLL gene. 33 While several studies have indicated that enforced Hox gene expression in murine models promotes leukemogenesis, the specific Hox-regulated mechanism(s) and pathways that promulgate leukemic cell growth and survival are not known.
In this study, we have used a stromal cell-dependent model of B-lineage ALL to determine how HoxA9 activity may promote stromal cell/growth factor independence. Using an inducible system, we found that HoxA9 activity resulted in prolonged proliferation in the absence of stromal cell support and that induction of HoxA9 activity resulted in IGF-1R expression. Inhibition of IGF-1R using either blocking antibodies (A12) or kinase inhibitors (AG1024) abrogated the proliferative effects in 
HoxA9 induced expression of IGF-1R
JT Whelan et al the presence of HoxA9 induction/activity. These findings were extended into cells that overexpress endogenous HoxA9 as a result of the MLL/AF4 oncoprotein. IGF-1R expression was found in SEMK2 and RS4;11 cells, both of which express MLL/ AF4 and HoxA9. IGF-1R expression was not observed in BLIN-3 cells that express MLL/AF4, but lack endogenous HoxA gene expression. 14 Proliferation of the factor-independent cell line, RS4;11, was inhibited upon inhibition of IGF-1R. siRNA 'knockdown' of endogenous HoxA9 in RS4;11 cells resulted in loss of IGF-1R expression.
Several lines of evidence suggest a role for IGF-1 and IGF-1R in leukemia. High levels of serum IGF-1 correlate with childhood leukemia and high birth weight. 34 Signaling via IGF-1/ IGF-1R interactions have been shown to participate in the growth and survival of multiple myeloma cells. 32, 35 IGF-1R expression has been reported in AML blasts and IGF-1 is capable of stimulating AML cell proliferation. 28, 29, 36, 37 Several studies have indicated that inhibition of IGF-1R signaling results in a reduction of cell proliferation and induction of apoptosis, particularly in AML. 28, 29, 37 Our data indicate that one mechanism of Hox-mediated cell proliferation is through expression and subsequent activation of the IGF-1R receptor. IGF-1R has been reported to relieve leukemic cells of cytokine dependency. 28, 29 IGF-1R activity is also implicated in several solid tumors, such as breast, prostate and colon, in which aberrant Hox gene expression has also been reported. [38] [39] [40] IGF-1R has been reported to be regulated by the c-Myb transcription factor. [25] [26] [27] In a recent report, expression of MLL/ENL resulted in increased c-Myb expression. 24 In our study, c-Myb levels were increased upon induction of HoxA9 activity. This suggests a model in which overexpression of HoxA9 results in increased expression of c-Myb and induction of IGF-1R expression. This would, in turn, promote stromal cell/growth factor-independent growth and survival, provided that IGF-1 was present. Our data indicate that IGF-1 is expressed by both the stromal and the leukemic cells used in this system (Figure 7) .
Recent work from the laboratory of Martelli 37 indicates that autocrine signaling from IGF-1 and IGF-1R promotes the growth of AML cells. These investigators reported that inhibition of IGF-1R in AML cells induced dephosphorylation of IGF-1R and apoptosis. This same study also reported that chemoresistance in AML cells correlated with IGF-1 secretion. As HoxA9 is frequently overexpressed in AML, 7 our study documenting HoxA9-mediated induction of IGF-1R expression is consistent with this recent report describing a role for IGF-1/IGF-1R signaling in AML.
Therapeutics targeting IGF-1R have been successful in a variety of oncogenic settings. 35, 41 IGF-1R activation affects multiple cellular pathways leading to increased proliferation, loss of apoptotic sensitivity and anchorage-dependent growth. 42 In addition, IGF-1R signaling is required for normal B-cell development, during the pro-B-to pre-B-cell transition. 43, 44 One study demonstrated that proliferation of the pre-B-ALL cell line, REH, could be inhibited in a dose-dependent manner by mAbs against IGF-I and IGF-1R. 45 Furthermore, treatment of IGF-1/insulin-dependent hematopoietic precursor cell lines with anti-IGF-1R mAbs induced growth arrest. 31, 32 Our findings herein suggest that inhibition of IGF-1R may be a good approach for leukemia or other cancers that exhibit elevated Hox gene expression; either as a stand-alone therapy or in combination with other approaches.
In total, 80% of infant ALL is associated with MLL aberrations, for which overexpression of HoxA9 is a hallmark. 5 In addition, high levels of serum IGF-1 and high birth weight have been reported to correlate with infant ALL; the so-called big baby hypothesis. 34 Thus, one area in which inhibition of IGF-1R may be of benefit is as a potential therapeutic in MLL positive, infant ALL.
In summary, our present data support a novel mechanistic role for HoxA9 activity in the promotion of leukemic cell growth via induction of IGF-1R expression. This pathway will yield new potential targets for the treatment of leukemia and other cancers that involve Hox gene overexpression.
